Plasma insulin-like growth factor in primary breast cancer patients treated with adjuvant chemotherapy.

Insulin-like growth factor 1 (IGF-1) plasma level was assayed in 60 breast cancer patients undergoing six courses of adjuvant chemotherapy. The only observed variation was a slight decrease (10%) in IGF-1 concentrations, assayed before treatment, between the first and the second courses of chemother...

Descripción completa

Detalles Bibliográficos
Autores principales: Peyrat, J. P., Révillion, F., Bonneterre, J.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1998
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150068/
https://www.ncbi.nlm.nih.gov/pubmed/9635846
_version_ 1782144566950887424
author Peyrat, J. P.
Révillion, F.
Bonneterre, J.
author_facet Peyrat, J. P.
Révillion, F.
Bonneterre, J.
author_sort Peyrat, J. P.
collection PubMed
description Insulin-like growth factor 1 (IGF-1) plasma level was assayed in 60 breast cancer patients undergoing six courses of adjuvant chemotherapy. The only observed variation was a slight decrease (10%) in IGF-1 concentrations, assayed before treatment, between the first and the second courses of chemotherapy. During chemotherapy courses, there were no statistically significant variations in IGF-1. These results suggest that chemotherapy, unlike the specific hormonal treatments tamoxifen and somatostatin, certainly does not act via a decrease in plasma IGF-1.
format Text
id pubmed-2150068
institution National Center for Biotechnology Information
language English
publishDate 1998
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-21500682009-09-10 Plasma insulin-like growth factor in primary breast cancer patients treated with adjuvant chemotherapy. Peyrat, J. P. Révillion, F. Bonneterre, J. Br J Cancer Research Article Insulin-like growth factor 1 (IGF-1) plasma level was assayed in 60 breast cancer patients undergoing six courses of adjuvant chemotherapy. The only observed variation was a slight decrease (10%) in IGF-1 concentrations, assayed before treatment, between the first and the second courses of chemotherapy. During chemotherapy courses, there were no statistically significant variations in IGF-1. These results suggest that chemotherapy, unlike the specific hormonal treatments tamoxifen and somatostatin, certainly does not act via a decrease in plasma IGF-1. Nature Publishing Group 1998-05 /pmc/articles/PMC2150068/ /pubmed/9635846 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Peyrat, J. P.
Révillion, F.
Bonneterre, J.
Plasma insulin-like growth factor in primary breast cancer patients treated with adjuvant chemotherapy.
title Plasma insulin-like growth factor in primary breast cancer patients treated with adjuvant chemotherapy.
title_full Plasma insulin-like growth factor in primary breast cancer patients treated with adjuvant chemotherapy.
title_fullStr Plasma insulin-like growth factor in primary breast cancer patients treated with adjuvant chemotherapy.
title_full_unstemmed Plasma insulin-like growth factor in primary breast cancer patients treated with adjuvant chemotherapy.
title_short Plasma insulin-like growth factor in primary breast cancer patients treated with adjuvant chemotherapy.
title_sort plasma insulin-like growth factor in primary breast cancer patients treated with adjuvant chemotherapy.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150068/
https://www.ncbi.nlm.nih.gov/pubmed/9635846
work_keys_str_mv AT peyratjp plasmainsulinlikegrowthfactorinprimarybreastcancerpatientstreatedwithadjuvantchemotherapy
AT ravillionf plasmainsulinlikegrowthfactorinprimarybreastcancerpatientstreatedwithadjuvantchemotherapy
AT bonneterrej plasmainsulinlikegrowthfactorinprimarybreastcancerpatientstreatedwithadjuvantchemotherapy

Ejemplares similares